ST3GAL2

Across TCGA pan-cancer cohorts, ST3GAL2 RNA is linked to patient survival in 27 of 34 cancer types, making it the most broadly survival-associated ST3GAL2 data layer compared with 7 for mutation status and 1 for mass-spec protein.

The strongest signal is observed in mesothelioma (MESO), where higher ST3GAL2 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated ST3GAL2 expression acts as an unfavorable survival marker, although some lineages such as PAAD and UCS show a favorable association.

MESO, KIRP, and ACC are the cancer types where ST3GAL2 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	OS	Median	II,III,IV	0.278	0.505	<.001	123	view →
KIRP	OS	Tertile	II,III,IV	0.236	0.678	<.001	76	view →
ACC	DFS	Median	All	0.238	0.645	<.001	68	view →
PAAD	DFS	Quartile	II,III,IV	0.533	0.249	<.001	56	view →
LUSC	DFS	Median	III,IV	0.417	0.996	.001	43	view →
LIHC	DFS	Median	All	0.201	0.361	<.001	42	view →
UCS	OS	Median	All	0.704	0.396	.003	40	view →
LGG	OS	Tertile	All	0.729	0.873	<.001	36	view →
UCEC	DFS	Median	IV	0.840	0.547	.008	28	view →
BLCA	DFS	Tertile	All	0.455	0.562	.026	22	view →
KIRC	DFS	Median	All	0.764	0.510	<.001	20	view →
HNSC	DFS	Tertile	IV	0.506	0.287	.010	17	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 27 lineages.

ST3GAL2–MESO (OS)

Open the MESO breakdown →